Liver News and Research

RSS

FDA calls for cuts in Acetaminophen in painkillers

The US FDA has asked for a limit on the amount of acetaminophen in prescription pain medicines in an effort to reduce the risk of liver damage. The announcement yesterday asked manufacturers to limit combination drugs such as the opioids Percocet and Vicodin to 325 milligrams of acetaminophen per pill and asked them to carry a “black box” warning about potential liver failure. At present these combinations carry up to 750 milligrams of acetaminophen.

13 Jan 2011

BioCryst reports positive results from peramivir Phase 3 study in influenza

BioCryst Pharmaceuticals, Inc. today announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program.

13 Jan 2011

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

VistaGen Therapeutics, Inc. and NuPotential, Inc. today announced that the National Heart, Lung and Blood Institute of the U.S. National Institutes of Health (NIH) has awarded to the companies a grant of approximately $500,000 to accelerate development of novel and safer approaches to generate patient-specific induced pluripotent stem (iPS) cells for regenerative medicine, drug discovery and drug rescue.

13 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

BPA more harmful to women with hormonal and fertility imbalances

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), found higher Bisphenol A (BPA) levels in women with polycystic ovary syndrome (PCOS) compared to controls. Furthermore, researchers found a statistically significant positive association between male sex hormones and BPA in these women suggesting a potential role of BPA in ovarian dysfunction.

13 Jan 2011

Emerging Healthcare enters option agreement with OceanBASIS

Emerging Healthcare Solutions, Inc. announced today that it has entered into an option agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.

12 Jan 2011

Bone marrow stem cell transplantation provides therapeutic benefit to patients with end-stage liver disease

Transplanting their own bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation. Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.

11 Jan 2011

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Vical Incorporated today announced a new publication summarizing results from the company's completed trials of Allovectin-7 including systemic responses and an excellent safety profile in patients with metastatic melanoma.

11 Jan 2011

Study to identify early warning biomarkers for presence of breast and prostate cancers

Using biological samples taken from patients and state-of-the-art biochemical techniques, a Florida State University researcher is working to identify a variety of "biomarkers" that might provide earlier warnings of the presence of breast and prostate cancers.

11 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

New insights into estrogen receptor beta

Research with significant implications in the treatment and intervention of cancer and obesity has been published recently in two prestigious journals by University of Houston (UH) biochemist Dr. Jan--ke Gustafsson.

11 Jan 2011

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

UCLA researchers have found that a protein that plays an important role in some antioxidant therapies may not be as effective due to additional mechanisms that cause it to promote atherosclerosis, or clogging of the arteries.

11 Jan 2011

Slowing engines of mitochondria could extend life

In making your pro-longevity resolutions, like drinking more red wine and maintaining a vibrant social network, here's one you likely forgot: dialing down your mitochondria. It turns out that slowing the engines of these tiny cellular factories could extend your life-an observation relevant not only to aging research but to our understanding of how cells communicate with each another.

10 Jan 2011

FDA, EMA accept boceprevir for expedited review

Merck, known as MSD outside the United States and Canada, announced today that regulatory applications for boceprevir, Merck's investigational oral hepatitis C virus (HCV) protease inhibitor, were submitted in 2010 and have been accepted for expedited review in both the U.S. and the European Union.

10 Jan 2011

Study finds link between nonalcoholic fatty liver disease and stroke

People suffering from fatty liver disease may be three times more likely to suffer a stroke than individuals without fatty liver, according to a study by researchers at St. Michael's Hospital and the London Health Sciences Centre.

10 Jan 2011

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Entelos, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,853,406 entitled "Predictive Toxicology for Biological Systems" to the Company.

9 Jan 2011

Vaccines for alcoholism and cocaine addiction coming soon

In a latest development, researchers from Chile have come up with a vaccine to cure alcoholics. It will help them kick the habit by creating a sensation of a terrible hangover after just a few drinks. The mechanism by which this vaccine acts is by neutralizing a group of enzymes that help the body to break down alcohol. When the enzymes aldehyde dehydrogenase is disabled the body accumulates the alcohol to create the hangovers after just a few drinks.

9 Jan 2011

Positive results from LifeCycle Pharma's LCP-Tacro comparative trial in de novo liver transplant patients

LifeCycle Pharma A/S has announced positive top-line results from a Phase 2 clinical trial involving 58 patients comparing LCP-Tacro™ tablets administered once-daily versus Prograf® (tacrolimus) capsules (Astellas Pharma) administered twice-daily in de novo liver transplant patients for one year.

7 Jan 2011

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys, Inc. today announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem to patients being treated for leukemia or other blood born cancers.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Liver News and Research

FDA calls for cuts in Acetaminophen in painkillers

BioCryst reports positive results from peramivir Phase 3 study in influenza

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

BPA more harmful to women with hormonal and fertility imbalances

Emerging Healthcare enters option agreement with OceanBASIS

Bone marrow stem cell transplantation provides therapeutic benefit to patients with end-stage liver disease

Positive results from Allovectin-7 Phase 3 trial in patients with metastatic melanoma

Study to identify early warning biomarkers for presence of breast and prostate cancers

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

New insights into estrogen receptor beta

Study: Protein that plays a key role in some antioxidant therapies can promote atherosclerosis

Slowing engines of mitochondria could extend life

FDA, EMA accept boceprevir for expedited review

Study finds link between nonalcoholic fatty liver disease and stroke

Entelos receives U.S. Patent for Predictive Toxicology for Biological Systems

Vaccines for alcoholism and cocaine addiction coming soon

Positive results from LifeCycle Pharma's LCP-Tacro comparative trial in de novo liver transplant patients

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News